Please provide your email address to receive an email when new articles are posted on . A single dose of zoledronic acid effectively maintains large and rapid gains in spine and hip bone mineral ...

Recent data demonstrate that when using zoledronic acid to reduce the risk of skeletal-related events in metastatic breast cancer, metastatic prostate cancer, and multiple myeloma, the dosing interval ...

June 4, 2009 — The FDA this month has approved zoledronic acid infusion (Reclast, Novartis Pharmaceuticals Corp) for the prevention of postmenopausal osteoporosis during a 2-year period. "It is very ...

Zoledronic acid is effective in the prevention of bone loss in premenopausal women with breast cancer being treated with endocrine therapy. The benefit of zoledronic acid probably extends for some ...

March 24, 2006 (Nice, France) — Women who receive zoledronic acid (Zometa) at the initiation of breast cancer treatment with letrozole (Femara) have less bone loss than those for whom treatment is ...

Please provide your email address to receive an email when new articles are posted on . “Discontinuation of denosumab results in high-turnover bone loss and increased fracture risk,” Sabashini ...